Keywords: Shire, Third quarter 2009 results, Adderall
Shire’s new drugs offset slumping Adderall in 3rd quarter 2009
Article | 02 November 2009
Shire, the UK’s third largest drugmaker, posted revenues from continuing operations for the three months to September 30, 2009 down 14% to $667.0 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
